Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability

Cancer Research

Volumn 74, Issue 15, 2014, Pages 4111-4121

  Kuruppu, Darshini ^a   Brownell, Anna Liisa ^a   Shah, Khalid ^a   Mahmood, Umar ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; 9 [4 18F FLUORO 3 (HYDROXYMETHYL)BUTYL]GUANINE; GUANINE DERIVATIVE; UNCLASSIFIED DRUG; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER CELL DESTRUCTION; CANCER CELL LINE; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NEOPLASM; NONHUMAN; ONCOLOGICAL PROCEDURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TUMOR CELL DESTRUCTION; TUMOR VIABILITY; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL ONCOLYSIS; VIRION; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHLOROCEBUS AETHIOPS; COLONIC NEOPLASMS; FEMALE; HT 29 CELL LINE; LUMINESCENCE; MELANOMA, AMELANOTIC; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SCINTISCANNING; TUMOR CELL LINE; VERO CELL LINE; VIROLOGY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; LUMINESCENT MEASUREMENTS; MELANOMA, AMELANOTIC; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POSITRON-EMISSION TOMOGRAPHY; VERO CELLS;

EID: 84905482196     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3472     Document Type: Article

References (38)

1. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci U S A 1996;93:11307-12.
2. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000;105:841-6.
3. Mullen JT, Tanabe KK. Viral oncolysis. Oncologist 2002;7:106-19.
4. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50.
5. Todo T. Armed oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr 2008;2:208-13.
6. Park K, Kim WJ, Cho YH, Lee YI, Lee H, Jeong S, et al. Cancer gene therapy using adeno-associated virus vectors. Front Biosci 2008;13:2653-9.
7. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4.
8. Kuruppu D, Tanabe KK. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther 2005;4:524-31.
9. Reinblatt M, Pin RH, Fong Y. Herpes viral oncolysis: a novel cancer therapy. J Am Coll Surg 2007;205:S69-75.
10. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988;62:196-205.
11. Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S, et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004;64:2561-7.
12. El-Deiry WS, Sigman CC, Kelloff GJ. Imaging and oncologic drug development. J Clin Oncol 2006;24:3261-73.
13. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter geneexpressionin livingmice. ProcNatlAcadSciUSA 2002;99:377-82.
14. Dothager RS, Flentie K, Moss B, Pan MH, Kesarwala A, Piwnica-Worms D. Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 2009;20:45-53.
15. Shah K, Weissleder R. Molecularopticalimaging: applications leadingto the development of present day therapeutics. NeuroRx 2005;2:215-25.
16. Luker KE, Luker GD. Bioluminescence imaging of reporter mice for studies of infection and inflammation. Antiviral Res 2010;86:93-100.
17. Ray P, Tsien R, Gambhir SS. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res 2007;67:3085-93.
18. Haddad D, Chen CH, Carlin S, Silberhumer G, Chen NG, Zhang Q, et al. Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter. PLoS One 2012;7:e41647.
19. Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 2002;43:1072-83.
20. Alauddin MM, Gelovani JG. Radiolabeled nucleoside analogues for PET imaging of HSV1-tk gene expression. Curr Top Med Chem 2010;10:1617-32.
21. Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y, et al. Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res 2007;67:3295-300.
22. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000;14:301-11.
23. Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent sitespecific recombinases. BMC Biotechnol 2006;6:40.
24. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996;224:323-9.
25. ClinicalTrials. Gov Identifier: NCT01071941.
26. Moussavi M, Fazli L, Tearle H, Guo Y, Cox M, Bell J, et al. Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res 2010;70:1367-76.
27. Sadikot RT, Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc 2005;2:537-40.
28. Serganova I, Moroz E, Vider J, Gogiberidze G, Moroz M, Pillarsetty N, et al. Multimodality imaging of TGFb signaling in breast cancer metastases. FASEB J 2009;23:2662-72.
29. Hawes JJ, Reilly KM. Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis. Toxicol Pathol 2010;38:123-30.
30. Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, et al. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res 2008;68:4506-10
31. Jang SJ, Kang JH, Kim KI, Lee TS, Lee YJ, Lee KC, et al. Application of bioluminescence imaging to therapeutic intervention of herpes simplex virus type 1-thymidine kinase/ganciclovir in glioma. Cancer Lett 2010;297:84-90.
32. Tsuruta Y, Pereboeva L, Breidenbach M, Rein DT, Wang M, Alvarez RD, et al. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 2008;14:3582-8.
33. Argnani R, Marconi P, Volpi I, Bolanos E, Carro E, Ried C, et al. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. Liver Int 2011;31:1542-53.
34. Burgos JS, Guzman-Sanchez F, Sastre I, Fillat C, Valdivieso F. Noninvasive bioluminescence imaging for monitoring herpes simplex virus type 1 hematogenous infection. Microbes Infect 2006;8:1330-8.
35. Hwang S, Wu TT, Tong LM, Kim KS, Martinez-Guzman D, Colantonio AD, et al. Persistent gammaherpesvirus replication and dynamic interaction with the host in vivo. J Virol 2008;82:12498-509.
36. Yamamoto S, Deckter LA, Kasai K, Chiocca EA, Saeki Y. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther 2006;13:1731-6.
37. Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, et al. Monitoring the efficacy of adoptively transferred prostate cancertargeted human T lymphocytes with PET & bioluminescence imaging. J Nucl Med 2008;49:1162-70.
38. Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003;22:6865-72.